Bristol-Myers Squibb Posts Strong 2025 Results as Growth Portfolio Drives Price Target Hikes

Bristol-Myers Squibb (BMY) reported robust financial results for the fourth quarter and fiscal year 2025, with annual revenues reaching $48.2 billion. The company's Growth Portfolio saw a significant expansion of 16-17%, primarily fueled by the strong performance of its core drug, Eliquis. Following these results, analysts at Bernstein SocGen Group and Wells Fargo raised their price targets for the stock, citing the strength of the core business. The company's differentiated pipeline is expected to sustain growth well into the 2030s, according to market experts. This operational momentum allowed the firm to exceed market expectations and solidify its position in the healthcare sector. With double-digit growth in key segments and positive analyst revisions, the outlook for BMY remains bullish.